Cargando…

Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach

Genetic mutations and aberrant epigenetic alterations are the triggers for carcinogenesis. The emergence of the drugs targeting epigenetic aberrations has provided a better outlook for cancer treatment. Histone deacetylases (HDACs) are epigenetic modifiers playing critical roles in numerous key biol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ranganna, Kasturi, Selvam, Chelliah, Shivachar, Amruthesh, Yousefipour, Zivar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7662987/ https://www.ncbi.nlm.nih.gov/pubmed/33147762 http://dx.doi.org/10.3390/ijms21218198

Ejemplares similares

Cellular Effects of Butyrate on Vascular Smooth Muscle Cells are Mediated through Disparate Actions on Dual Targets, Histone Deacetylase (HDAC) Activity and PI3K/Akt Signaling Network
por: Mathew, Omana P., et al.
Publicado: (2019)

Curation and Analysis of Multitargeting Agents for Polypharmacological Modeling
por: Reddy, A. Srinivas, et al.
Publicado: (2014)

Epigenetic polypharmacology: from combination therapy to multitargeted drugs
por: de Lera, Angel R., et al.
Publicado: (2016)

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013)

Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 Inhibitors
por: Martínez, Regina, et al.
Publicado: (2020)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

The Polypharmacological Effects of Cannabidiol
por: Castillo-Arellano, Jorge, et al.
Publicado: (2023)

Advances in Computational Polypharmacology
por: Feldmann, Christian, et al.
Publicado: (2022)

SIRT6 histone deacetylase functions as a potential oncogene in human melanoma
por: Garcia-Peterson, Liz Mariely, et al.
Publicado: (2017)

Computational polypharmacology comes of age
por: Rastelli, Giulio, et al.
Publicado: (2015)

Structural and Functional View of Polypharmacology
por: Moya-García, Aurelio, et al.
Publicado: (2017)

Deficiency of Splicing Factor 1 (SF1) Reduces Intestinal Polyp Incidence in Apc(Min/)(+) Mice
por: Godavarthi, Jyotsna D., et al.
Publicado: (2020)

Regulation of cellular contractile force, shape and migration of fibroblasts by oncogenes and Histone deacetylase 6
por: López-Guajardo, Ana, et al.
Publicado: (2023)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Automated design of ligands to polypharmacological profiles
por: Besnard, Jérémy, et al.
Publicado: (2012)

Exploiting kinase polypharmacology for nerve regeneration
por: Al-Ali, Hassan, et al.
Publicado: (2016)

How polypharmacologic is each chemogenomics library?
por: Ni, Eric, et al.
Publicado: (2020)

Polypharmacology of ambroxol in the treatment of COVID-19
por: Wang, Ziyuan, et al.
Publicado: (2023)

Polypharmacology: promises and new drugs in 2022
por: Ryszkiewicz, Piotr, et al.
Publicado: (2023)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Histone deacetylase inhibitors blocked activation and caused senescence of corneal stromal cells
por: Zhou, Qingjun, et al.
Publicado: (2008)

The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy
por: Samant, Sadhana A., et al.
Publicado: (2017)

Histone deacetylase-2 is involved in stress-induced cognitive impairment via histone deacetylation and PI3K/AKT signaling pathway modification
por: Wu, Jie, et al.
Publicado: (2017)

Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma
por: Ruf, Benjamin, et al.
Publicado: (2015)

The Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications
por: Kinnings, Sarah L., et al.
Publicado: (2010)

The kinase polypharmacology landscape of clinical PARP inhibitors
por: Antolin, Albert A., et al.
Publicado: (2020)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption
por: Young, David A, et al.
Publicado: (2005)

Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer
por: Bi, Jianling, et al.
Publicado: (2022)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC‐202 blocks oncogenic hedgehog‐GLI signaling and overcomes smoothened inhibitor resistance
por: Gruber, Wolfgang, et al.
Publicado: (2017)

Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
por: Maneix, Laure, et al.
Publicado: (2022)

Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
por: Huang, Ying, et al.
Publicado: (2011)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

In silico polypharmacology: retrospective recognition vs. rational design
por: Proschak, Ewgenij
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4qgfqv3a0r2rjvo6dita6vucjp